NC
ALXO icon

NinePointTwo Capital’s ALX Oncology ALXO Stock Holding History

NinePointTwo Capital’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,257
Closed -$240K – 202
2022
Q1 		$240K Hold
14,257
– – 0.06% 164
2021
Q4 		$306K Buy
+14,257
New +$615K 0.1% 55

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NinePointTwo Capital's ALXO Position: Q2 2022 in Review

NinePointTwo Capital sold out of ALX Oncology (ALXO) in Q2 2022, closing a stake of 14,257 shares — an estimated $240K sold.

NinePointTwo Capital first reported a position in ALXO in Q4 2021 and held it in 2 quarters. The position peaked at $306K in Q4 2021. 97 funds tracked by Wall St. Rank hold ALXO as of Q2 2022.

  • NinePointTwo Capital reported no remaining ALX Oncology position as of Q2 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 14,257 ALX Oncology shares in Q2 2022, an estimated $240K.
  • NinePointTwo Capital first reported a position in ALX Oncology in Q4 2021 and held it in 2 quarters.
  • NinePointTwo Capital's ALX Oncology position peaked at $306K in Q4 2021.
  • 97 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2022.

Based on NinePointTwo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.